Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.
Delphi study
Parkinson's disease
apomorphine
deep-brain stimulation
infusion pump
intraintestinal infusion
levodopa-carbidopa drug combination
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
28
04
2022
received:
16
02
2022
accepted:
03
05
2022
pubmed:
25
5
2022
medline:
15
7
2022
entrez:
24
5
2022
Statut:
ppublish
Résumé
In the absence of widely accepted criteria, determining when a patient with Parkinson's disease (PD) may benefit from more advanced treatments such as device-aided therapy (DAT) so far remains a matter of physician judgment. This analysis investigates how classification of PD varies across countries relative to measures of disease severity. The OBSERVational, cross-sEctional PD (OBSERVE-PD) study included consecutive patients with PD at centers that offer DATs in 18 countries. In this subgroup analysis, we explore intercountry differences in identification of advanced versus non-advanced PD based on physician's clinical judgment, symptoms assessed using Delphi consensus criteria, use of DAT, motor and non-motor symptoms, and caregiver support. Demographic and clinical characteristics were obtained through review of medical records. Overall, 1342 of 2615 patients (51.3%) were assessed by physicians as having advanced PD. The proportion of patients in different countries identified as having advanced PD (24.4-82.2%) varied. In 15 of 18 countries, a greater proportion of patients with advanced PD, according to select Delphi criteria, were identified by physicians as having advanced PD than with non-advanced PD. There was a wide variability across countries in the proportion of patients with no dyskinesia, disabling dyskinesia, dyskinesia pain, and non-motor symptoms who were identified by physicians as having advanced versus non-advanced PD. The proportion of patients identified with advanced PD symptoms varies widely across countries, despite differences on the patients' profiles, indicating a need for objective diagnostic criteria to help identify patients who may benefit from DAT.
Identifiants
pubmed: 35607843
doi: 10.1111/ane.13648
pmc: PMC9541702
doi:
Substances chimiques
Antiparkinson Agents
0
Drug Combinations
0
Gels
0
Levodopa
46627O600J
Carbidopa
MNX7R8C5VO
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-176Subventions
Organisme : AbbVie
Informations de copyright
© 2022 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd.
Références
Neuropsychiatr Dis Treat. 2019 Nov 13;15:3187-3195
pubmed: 32009788
Swiss Med Wkly. 2021 Mar 06;151:w20419
pubmed: 33705561
BMC Neurol. 2022 Jan 28;22(1):41
pubmed: 35090406
Eur Neuropsychopharmacol. 2011 Feb;21(2):180-91
pubmed: 20888737
J Neural Transm (Vienna). 2017 Dec;124(12):1529-1537
pubmed: 29116411
Parkinsonism Relat Disord. 2021 Nov;92:59-66
pubmed: 34695657
Front Hum Neurosci. 2019 Aug 08;13:269
pubmed: 31440150
Parkinsons Dis. 2021 Jan 25;2021:6635618
pubmed: 33564391
Curr Med Res Opin. 2018 Dec;34(12):2063-2073
pubmed: 30016901
J Clin Neurosci. 2013 Jan;20(1):102-6
pubmed: 23098389
J Med Assoc Thai. 2011 Jun;94(6):749-55
pubmed: 21696087
Neurodegener Dis Manag. 2020 Oct;10(5):309-323
pubmed: 32873195
Parkinsonism Relat Disord. 2009 Dec;15(10):728-41
pubmed: 19805000
Health Policy. 2014 Jan;114(1):5-14
pubmed: 24054709
Parkinsonism Relat Disord. 2013 Jun;19(6):628-33
pubmed: 23514630
BMC Neurol. 2019 Apr 2;19(1):50
pubmed: 30940119
Lancet Neurol. 2018 Nov;17(11):939-953
pubmed: 30287051
Brain Behav. 2020 Sep;10(9):e01753
pubmed: 32683797
Neuroepidemiology. 2017;48(3-4):131-137
pubmed: 28728161
Pract Neurol. 2014 Oct;14(5):310-22
pubmed: 24699931
Acta Neurol Scand. 2022 Aug;146(2):167-176
pubmed: 35607843
Ideggyogy Sz. 2020 Jul 30;73(7-08):261-268
pubmed: 32750243
Clin Park Relat Disord. 2020 Oct 17;4:100075
pubmed: 34316660